Just had a look at the LinkedIn post - the calibre of people who have ticked this up is pretty impressive - Commercial lead @ Pfizer, Medical Director @ Novartis, Global Head Oncology @ Roche - well we are certainly on Big Pharma's radar that's for sure.
This is hands down the best RNS from NFX in years. Dan promised some news before year end and he has delivered. Hopefully 2023 can see NXP0004 licensed out giving plenty of money to develop NXP0002 to it's full potential.
It is definitely great to see Dan back again. Good presentation and clarification of the financing deal by Tim. Finance is fine and there is enough money coming in monthly to certainly keep the lights on.
2023 could potentially be a great year if we can license out NXP2.
I'm sure the is an 'N' missing in the ticker ACUT - just can't think where it would be though :-)
https://twitter.com/TheEthicalTout/status/1502372865743757324?t=m3p1IGXu3tC5LOXpPkmezA&s=09
EU banning on Iron & Steel from Russia. That's approx 20 Million tonnes of iron ore (per year) that will need to be sourced from elsewhere.
If only there was some iron ore just sitting around that could be shipped quickly...
Pensana is up 13% today - MKA is very frustrating - been going backwards for months now. Even though we've had decent news re TR1s, support of Malawi govt... No sure what it's going to take to give this share a kick up the a$$.
I suspect @Myles may be selling as very unusual for him not to comment on yesterday's RNS.
Certainly getting a bit more exposure
Tweet from Cadence
https://twitter.com/CadenceMinerals/status/1495702099237220352?s=20&t=gRMW6IK_X3HNQk4F7UB2Ag
https://www.thisismoney.co.uk/money/share-investing/article-10528527/Clamour-lithium-power-portfolio.html
It was actually very good. Reminds me of 2020 and all the potential we saw.
Just a few points:
1. MS trial on 1st patient not only safe but patient showed clinical improvement. Data for 6 months of usage from this trial will be release in Q2 and they plan to do more trials in Europe.
2. IND for Crohns is being submitted - guess that might be the next RNS
3. Currently have $40m in the bank and costs this year for all the trials will be $28m - so fully funded going forward.
2021 was a train smash but it certainly looks like the good Dr has got his mojo back for 2022!
He struggled to keep a straight face when asked about how the share price was doing.
I think it's a case of let's get these trails started, file IND(s) and actually do some biotech work instead of ****ing around with admin matters. Think the market just needs to know someone is at home and the lights haven't been switched off.
Agreed - a complete train smash of a company. Almost seems like the BoD couldn't care less. as there has been virtually no activity for nearly a year. It's a shame as Foralumab in the right hands could actually be a fantastic drug!
Seems we are getting on more people's radar.
David Lenigas puts Cadence down as a potential 5 bagger. I'd say that's a pretty good start.
https://twitter.com/DavidLenigas/status/1480278726596255748?s=20
Well we've dropped to the placing price which is what most people expected. However I ask myself what is the risk/reward now in terms of the share price. It's possible we will fall maybe to around 6.5 - so perhaps another 10% or so. However what is the potential reward? Even at a modest 10p that's not shabby at all - I'll take that in this environment. But long term with A2 and then Vermelho I would hope we should be a lot higher.
I think you have to give credit to the BoD -for getting the deal done - not many AIM miners get to production at all. Think it's easy to forget that it wasn't that long ago that the share price was on it's knees at less than 2p.
100% off take with Glencore sounds good but I don't think I've seen the pricing so can't comment on how it impacts the key metrics. Whilst I'm not sure of the market reaction over the next few days I am pretty confident that we will see several multiples of today's price over the coming months.